Showing 5581-5590 of 8839 results for "".
- Positive Phase 2 Results Seen With Galderma’s Proprietary Liquid Toxin for Frown Lineshttps://practicaldermatology.com/news/positive-phase-2-results-seen-with-galdermas-proprietary-liquid-toxin-for-frown-lines-2/2460170/Galderma’s novel liquid abotulinum toxin, QM1114, is safe and effective for the treatment of glabellar lines, according to Phase 2 study results. Pivotal Phase 3 trials for Galderma's liquid formulation of botulinum toxin type A for the treatment of glabellar lines are expecte
- It's Grant Time: La Fondation La Roche-Posay Calls for Scientific Abstractshttps://practicaldermatology.com/news/its-grant-time-la-fondation-la-roche-posay-calls-for-scientific-abstracts/2460169/Calling all residents, fellows, and practitioners within their first five years of practice: La Fondation La Roche-Posay (North American) is now accepting submissions for their 2020 grants program. Three grants for $10,000, $5,000 & $5,000 will be awarded for innovative program
- Positive Top Line Results from Second Phase 3 Study of Abrocitinib for Atopic Dermatitishttps://practicaldermatology.com/news/positive-top-line-results-from-second-phase-3-study-of-abrocitinib-for-atopic-dermatitis-1/2460159/Pfizer Inc. shared positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherap
- Study: Recell System Plus Dermabrasion Speeds Acne Scar Healinghttps://practicaldermatology.com/news/study-recell-system-plus-dermabrasion-speeds-acne-scar-healing/2460154/When combined with dermabrasion, the RECELL Autologous Cell Harvesting Device speeds the healing of facial acne scars, according to a study in Aesthetic Plastic Surgery. The RECELL System uses a small
- Study: Long-Term Use of Brodalumab Is Safe, Effectivehttps://practicaldermatology.com/news/study-long-term-use-of-brodalumab-is-safe-effective/2460150/Long-term use of brodalumab (SILIQ) improved skin clearance and quality of life in patients with moderate-to-severe psoriasis, according to a new study in the American Journal of Clinical Dermatology. Ov
- With Fibrocell Acquisition, Castle Creek Expands Late-Stage EB Pipelinehttps://practicaldermatology.com/news/with-fibrocell-acquisition-castle-creek-expands-late-stage-eb-pipeline/2460149/Castle Creek Pharmaceutical Holdings, Inc. acquired Fibrocell Science, Inc., a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases. With the resources of CCP Holdings’ subsidiary,
- PE in Dermatology: NavaDerm Partners with Laser & Skin Surgery Center of NYhttps://practicaldermatology.com/news/pe-in-dermatology-navaderm-partners-with-laser-skin-surgery-center-of-ny/2460119/NavaDerm is partnering with Laser & Skin Surgery Center of New York, Midtown Dermatology and their affiliated entities. Navaderm is a dermatology services organization in the Northeast and a BelHealth Investm
- Vitamin A May Lower SCC Riskhttps://practicaldermatology.com/news/vitamin-a-may-lower-scc-risk/2460113/Higher vitamin A intake may reduce risk for cutaneous squamous cell carcinoma, a
- Sciton Targets Veins, Skin, and Hair with Clear Suitehttps://practicaldermatology.com/news/sciton-targets-veins-skin-and-hair-with-clear-suite/2460111/Sciton Inc. is launching its Clear Suite family of products. The Clear Suite offerings make the JOULE platform customizable. Utilizing the 1064 Nd:YAG wavelength, the Clear Suite family of products, including ClearV, ClearSilk, and ClearHair, combined with BroadBand Light (BBL), al
- New Cerave Poll Reveals Confusion about Healthy, Clean Skin and How to Achieve Ithttps://practicaldermatology.com/news/new-cerave-poll-reveals-confusion-about-healthy-clean-skin-and-how-to-achieve-it/2460108/Many of us are confused about what "clean" skin really means and how best to achieve it, according to an online survey commissioned by CeraVe.